Visão geral da empresa
A clinical-stage precision medicine pharmaceutical company, Allarity Therapeutics, Inc. focuses on the development of novel anti-cancer therapeutics designed to address significant unmet medical needs in oncology. The firm operates within the broader Healthcare sector and specifically within the Biotechnology industry, a classification that implies a reliance on intensive research and development cycles and regulatory approval processes before generating substantial commercial revenue. The company's current scale is defined by a market capitalization of $18.19 million, annual revenue of $320,000, and a workforce consisting of 7 employees. These specific valuation and revenue figures indicate that Allarity is an early-stage micro-cap entity with a very small operational footprint, suggesting that its primary value proposition lies in potential future pipeline assets rather than current cash flow generation or established market share.
Saúde financeira
The company reported revenue of $320,000 over the trailing twelve months, while simultaneously posting a net income of $-11,231,000 and an EBITDA of $-12,596,000. The substantial gap between the minimal revenue and the significant net loss reveals a cost structure dominated by heavy upfront expenditures, likely associated with clinical trials, personnel, and research initiatives that have not yet been offset by sales. The free cash flow stands at $-10,213,750, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from business activities. This negative cash flow profile means the company must rely on external capital raises or existing cash holdings to sustain its financial flexibility and continue its scientific programs. Margin analysis shows a gross margin of 100.0%, an operating margin of -911.9%, and a profit margin of 0.0%, where the high gross margin is typical for biotech firms before R&D costs are allocated, while the deeply negative operating margin reflects the intense investment required to bring products to market. The balance sheet holds $14.77 million in cash against $1.40 million in debt, supported by a debt-to-equity ratio of 14.24 and a current ratio of 2.13, indicating that while the firm carries leverage, it maintains sufficient short-term liquid assets relative to its current liabilities to cover obligations. Return on Equity is -103.8% and Return on Assets is -38.5%, metrics that reveal management is currently deploying capital to grow the business rather than generating returns for shareholders, a common characteristic in the early biotechnology development phase where profitability is not yet realized.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to the company's lack of positive earnings, whereas the forward P/E is -1.19, a figure that implies expected earnings are still negative in the near term and suggests valuation is currently driven by asset value and growth potential rather than earnings multiples. The price-to-book ratio is 1.88, indicating that the market values the company at a premium of 88% over its book value, which reflects investor optimism regarding the intrinsic value of the company's intellectual property and future pipeline despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 56.85 and an EV/EBITDA of -0.38 suggest that the stock is priced based on revenue multiples, a standard practice for pre-revenue or high-burn biotech companies where sales are projected to grow significantly in the future. The 52-week high is $2.35 and the 52-week low is $0.61, placing the current trading price within a wide range of volatility typical for small-cap biotechnology stocks. With a beta of 0.01, the stock exhibits extremely low price volatility relative to the broader market, suggesting its price movements are decoupled from general market indices and are instead driven almost exclusively by company-specific clinical trial results or strategic developments.
Growth & Income
The revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, reflecting the fact that the company has not yet achieved consistent commercial scaling to calculate meaningful growth rates. The absence of a dividend yield, which is listed as N/A, and a payout ratio of 0.0% confirms that the company does not distribute income to shareholders, as it must reinvest all available resources back into drug development and clinical operations. Since the firm is not a dividend payer, the capital that would otherwise be paid out is directed entirely toward sustaining the pipeline and pursuing the personalized treatment of cancer using drug-specific companion diagnostics. Consequently, the overall growth and income profile for Allarity Therapeutics is characterized by a complete lack of current income generation, with the entire financial strategy focused on long-term asset creation rather than short-term shareholder returns or dividend stability.